Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review Article

COVID-19 associated with pulmonary aspergillosis: A literature review

Chih-Cheng Lai a, Weng-Liang Yu b,c,*

a Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan
b Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan
c Department of Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

Received 3 August 2020; received in revised form 1 September 2020; accepted 12 September 2020
Available online 24 September 2020

KEYWORDS
Aspergillus
COVID-19
SARS-CoV-2
Co-infection

Abstract Bacterial or virus co-infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported in many studies, however, the knowledge on Aspergillus co-infection among patients with coronavirus disease 2019 (COVID-19) was limited. This literature review aims to explore and describe the updated information about COVID-19 associated with pulmonary aspergillosis. We found that Aspergillus spp. can cause co-infections in patients with COVID-19, especially in severe/critical illness. The incidence of IPA in COVID-19 ranged from 19.6% to 33.3%. Acute respiratory distress syndrome requiring mechanical ventilation was the common complications, and the overall mortality was high, which could be up to 64.7% (n = 22) in the pooled analysis of 34 reported cases. The conventional risk factors of invasive aspergillosis were not common among these specific populations. Fungus culture and galactomannan test, especially from respiratory specimens could help early diagnosis. Aspergillus fumigatus was the most common species causing co-infection in COVID-19 patients, followed by Aspergillus flavus. Although voriconazole is the recommended anti-Aspergillus agent and also the most commonly used antifungal agent, aspergillosis caused by azole-resistant Aspergillus is also possible. Additionally, voriconazole should be used carefully in the concern of complicated drug–drug interaction and enhancing cardiovascular toxicity on anti-SARS-CoV-2 agents. Finally, this review suggests that clinicians should keep alerting the possible occurrence of pulmonary aspergillosis in severe/critical COVID-19 patients, and aggressively microbiologic study in addition to SARS-CoV-2 via respiratory specimens should be indicated.

Copyright © 2020, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Since the first recognition of novel pneumonia in Wuhan, China at the end of 2019, its causative pathogen - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been detected soon and its associated infection - coronavirus disease 2019 (COVID-19) has rapidly developed worldwide.1-3 As of August 2, 2020, a total of 17,660,523 patients had been infected by SARS-CoV-2 and the overall fatality rate was 3.9% (n = 680,894).1 Although the whole world work hard to understand and manage SARS-CoV-2 infections, a lot of issues, including how to prevent its spread, the appropriate treatment and vaccination remains unclear in this COVID-19 pandemic.

In addition, coinfection between SARS-CoV-2 and other respiratory pathogens have become another serious concern in the treatment of patients with COVID-19.4-9 Many bacteria, such as Streptococcus pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila, Staphylococcus aureus, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa, and many viruses, such as influenza virus, rhinovirus/enterovirus, non-SARS-CoV-2 coronavirus, respiratory syncytial virus, parainfluenza, and metapneumovirus, have been reported as possible co-pathogens among COVID-19 patients.4-11 Rarely, co-fungal infections with COVID-19 were also reported and the reported pathogens included Candida, Cryptococcus, Mucorales and Aspergillus spp.5,4,9,12

Among these possible co-pathogens in COVID-19 patients, we should pay more attention to Aspergillus because invasive pulmonary aspergillosis (IPA) is difficult to diagnosis and can be associated with high morbidity and mortality.13-15 Co-infection of IPA in the severe influenza patients has been recently reported in the Netherlands, Belgium, Taiwan, and China.16 Based on the experience about severe influenza-associated IPA, IPA might comprise up to 17-29% of severe influenza patients and contributed to a high mortality rate of up to 67%.17 The IPA following respiratory viral infections has not only limited to influenza virus, but may also follow respiratory syncytial virus or parainfluenza virus, SARS, human herpesvirus 6, and adenovirus.18-21 However, the studies and knowledge about the association of COVID-19 with pulmonary aspergillosis have been limited. Therefore, we did a comprehensive review of literature reporting co-pulmonary aspergillosis in patients with COVID-19 to provide updated information.

Association between COVID-19 and aspergillosis

The role of interleukin-10

Interleukin (IL)-10 has a key function in the regulation of cellular immune responses and is involved in various inflammatory diseases.22 Highly elevated level of sera IL-6 and IL-10 in pandemic influenza (H1N1) patients may lead to disease progression.23 A rat model of aspergillosis was significantly associated with increased production of IL-10, which mediate the influx of phagocytic cells and might limit the extent of local tissue destruction of Aspergillus infection.24 However, greater Th2 responses (involving an increase of IL-10) or lesser Th1 responses, might be related to down-regulation of macrophage responses, and increase the host susceptibility to lethal Aspergillus infection.25,26 Collectively, post respiratory viral Th-2 immune response of increasing IL-10 followed by temporary Th1 immune depression predisposes to invasive aspergillosis.

Clinical manifestations of COVID-19 with pulmonary aspergillosis

Incidence

Several studies9,33-41 had reported the occurrence of COVID-19 associated with IPA. The largest series was shown by Zhu et al.9 in a local hospital in Jiangsu Province, China from January 22 to February 2, 2020, in which 23.3% (60/243) COVID-19 patients had co-infection with Aspergillus. Moreover, they found that pulmonary aspergillosis could
develop in patients with asymptomatic, mild, moderate, severe and critical COVID-19. However, no detailed clinical manifestations were described in this report. Additionally, two studies reported the incidence of co-IPA among COVID-19 patients requiring ICU admission was 20.6% (7/34) in Belgium and 19.6% (6/31) in Netherlands, respectively. In France, Alanio et al. showed the incidence of COVID-19 associated with IPA was 33.3% (9/27) among mechanically ventilated patients.

Demographic data and comorbidity

Another study in China between January and March 2020 by Wang et al. identified 8 (7.7%) of 104 COVID-19 patients who had IPA at the same time. The mean age of these 8 patients was 73 ± 13 years and all were male. Seven (87.5%) patients had various underlying diseases, including hypertension (n = 7), diabetes mellitus (n = 2), chronic obstructive pulmonary disease (COPD) (n = 7), chronic kidney disease (n = 2) and heart disease (n = 1). Six patients received corticosteroid treatment but none of them had immunodeficiency or cancer. Additionally, several case series or case reports including a total of 34 cases provided the detailed clinical characteristics of COVID-19 patients with aspergillosis (Table 1). They were widely reported from France (n = 11), Germany (n = 7), the Netherlands (n = 7), Belgium (n = 7), Italy (n = 1) and Austria (n = 1). Their mean age was 66.1 ± 12.3 years and 20 (58.8%) patients were ≥65 years. Man compromised 82.4% (n = 28) cases. Hypertension (n = 15), diabetes mellitus (n = 9), obesity (n = 7), COPD (n = 5), hypercholesterolemia (n = 5), and ischemia heart disease (n = 3) were common underlying diseases, but 5 (14.7%) patients did not have any comorbidity. At least one-third of patients had received systemic steroids. However, the European organization for research and treatment of cancer (EORTC) risk host factors for aspergillosis were uncommonly found in 2 of 9 patients in Alanio et al.’s study. Moreover, no patient in van Arkel et al.’s study, Koehler et al.’s study, and Lahmer et al.’s report were positive for the EORTC risk host factors.

Radiographic findings

Several studies reported the radiographic findings of COVID-19 associated pulmonary aspergillosis. Wang et al. showed that typical IPA presentation including nodules with cavities and dendritic signs could present in the early stage. Additionally, several radiographic findings, such as peripheral nodule, air crescent, reverse halo sign, nodular consolidation, ground-glass opacities, crazy paving pattern, pleural effusion, and pulmonary cysts were reported among patients with COVID-19-associated pulmonary aspergillosis by other reports.

Mycological diagnosis

Several mycological studies, including fungus culture, PCR, galactomannan tests, β-D-glucan test and rarely lateral-flow device were applied to detect the presence of Aspergillus spp among these patients. In the review of 34 cases, among 29 patients who had culture-confirmed aspergillosis, Aspergillus fumigatus was the most common pathogens (89.7%, n = 26), followed by Aspergillus flavus (6.9%, n = 2). In addition, one case of azole-resistant A. fumigatus was reported by Meijer et al. Furthermore, the levels of galactomannan in bronchoalveolar lavage (BAL) fluid were always higher than those in serum.

Therapy

Among the 34 reported cases, the lopinavir-ritonavir combination was the most common anti-SARS-CoV-2 agents, followed by azithromycin and hydroxychloroquine. Voriconazole was the most commonly used antifungal agents, followed by caspofungin, isavuconazole and liposomal amphotericin B, however, 8 patients (23.5%) did not receive any antifungal agent.

Complications and outcome

In the report by Wang et al., all IPA cases caused by A. fumigatus developed in patients with severe/critical COVID-19 after tested negative for SARS-CoV-2. ARDS was the most common complication (50%, n = 4), followed by liver damage (12.5%, n = 1) and acute kidney injury (12.5%, n = 1). All required intensive care unit (ICU) admission, and four required mechanical ventilation (MV). Each one needed continuous renal replacement therapy (CRRT) and extracorporeal membranes oxygenation (ECMO). Moreover, further multivariate analysis showed that older age, an initial β-lactamase inhibitor combination, MV and COPD were independent risk factors for IPA among COVID-19 patients. Consistent with Wang et al.’s study in China, the review of other 34 cases showed ARDS (n = 12, others had no report), respiratory failure requiring MV support (n = 28) and renal failure requiring renal replacement (n = 11) were common complications, which indicated that this population should be classified as severe/critical disease of COVID-19. Moreover, there were 22 deaths and the overall case fatality rate was 64.7% among these 34 cases.

Clinical significance

Overall, the findings of this review provide several important information. First, in addition to common bacteria and viruses, Aspergillus spp. can cause co-infections in patients with COVID-19, especially in severe/critical illness. Most importantly, the outcome of these patients was poor. ARDS requiring MV support was the common complications, and the overall mortality was high. Second, the conventional risk factors of invasive aspergillosis were not common among these specific populations. Therefore, clinicians should keep alert on the possible occurrence of co-infection with Aspergillus in COVID-19 patients. Fungus culture and galactomannan test, especially from respiratory specimens could help early diagnosis. Third, A. fumigatus was the most common species causing co-infection in COVID-19 patients, followed by A. flavus. Although voriconazole is the recommended anti-Aspergillus agent and...
### Table 1  Clinical characteristics of patients co-infected with COVID-19 and pulmonary aspergillosis.

| Study/case | Age/gender | Underlying disease | Systemic steroid | Images | MV | RRT | Anti-COVID-19 | Antifungal treatment | Outcome | Culture/PCR (CT) | Galactomannan index | Blood | BAL |
|------------|------------|--------------------|------------------|--------|----|-----|--------------|---------------------|---------|-----------------|-------------------|-------|-----|
| Alanio et al. in France | 1 | 53/M | HTN, obesity, ischemia heart disease | Yes | NR | No | Yes | Yes | LPV-RTV | None | Alive | NG/neg | 0.13 | 0.89 |
| | 2 | 59/F | HTN, DM, obesity | No | NR | No | Yes | No | LRV-RTV, AZI | None | Alive | A. fumigatus/neg | 0.04 | 0.03 |
| | 3 | 69/M | HTN, obesity | Yes | NR | No | Yes | No | LPV-RTV | None | Alive | A. fumigatus/23.9 | 0.03 | ND |
| | 4 | 63/F | HTN, DM, ischemia heart disease | Yes | NR | No | Yes | Yes | LPV-RTV | None | Death | NG/neg | 0.51 | 0.15 |
| | 5 | 43/M | Asthma | Yes | NR | No | Yes | No | AZI | None | Alive | A. fumigatus/neg | 0.04 | 0.12 |
| | 6 | 79/M | HTN | Yes | NR | No | Yes | No | LPV-RTV, HCQ, AZI | None | Alive | A. fumigatus/34.5 | 0.02 | 0.05 |
| | 7 | 77/M | HTN, asthma | Yes | NR | No | Yes | Yes | LRV-RTV, HCQ, AZI | VRC | Death | A. fumigatus/29.0 | 0.37 | 3.91 |
| | 8 | 75/F | HTN, DM | Yes | NR | No | Yes | No | LPV-RTV, AZI | CSP | Death | A. fumigatus/31.7 | 0.37 | 0.36 |
| | 9 | 47/M | Myeloma | Yes | NR | No | Yes | No | No | None | Death | A. fumigatus/neg | 0.09 | ND |
| Rutsaert et al. in Belgium | 10 | 86/M | Hypercholesterolemia | NR | NR | NR | Yes | NR | NR | None | Death | A. flavus/NR | 0.10 | ND |
| | 11 | 38/M | Obesity, hypercholesterolemia | NR | NR | NR | Yes | NR | NR | VRC, ISA | Alive | A. fumigatus/ND | 0.30 | >2.8 |
| | 12 | 62/M | DM | NR | NR | NR | Yes | NR | NR | VRC | Death | A. fumigatus/ND | 0.20 | 2.00 |
| | 13 | 73/M | DM | NR | NR | NR | Yes | NR | NR | VRC | Alive | A. fumigatus/ND | 0.10 | >2.80 |
| | 14 | 77/M | DM, CKD, HTN, pemphigus foliaceus | NR | NR | NR | Yes | NR | NR | VRC | Alive | A. fumigatus/ND | 0.10 | 2.79 |
| | 15 | 55/M | HIV, HTN, hypercholesterolemia | NR | NR | NR | Yes | NR | NR | VRC, ISA | Death | NG/ND | 0.80 | 0.69 |
| | 16 | 75/M | AML, IPA (2012) | NR | NR | NR | Yes | NR | NR | VRC | Death | A. fumigatus/ND | ND | 2.63 |
| van Arkel et al. in Netherland | 17 | 83/M | Cardiomyopathy | Yes | NR | NR | NR | NR | NR | LPV-RTV, HCQ | VRC and AFG combination (n = 5), liposomal AMB (n = 1) | Death | A. fumigatus/ND | 0.4 | ND |
| | 18 | 67/M | COPD, NSCLC post RT | Yes | NR | NR | NR | NR | NR | LPV-RTV, HCQ | Death | A. fumigatus/ND | NR | ND |
| | 19 | 75/M | COPD | No | NR | NR | Yes | NR | NR | AMB (n = 1) | Death | A. fumigatus/ND | NR | 4 |
| | 20 | 43/M | None | No | NR | NR | Yes | NR | NR | LPV-RTV, HCQ | Death | A. fumigatus/ND | 0.1 | 3.8 |
| | 21 | 57/M | Asthma | No | NR | NR | No | NR | NR | LPV-RTV, HCQ | Death | A. fumigatus/ND | 0.1 | 1.6 |
| | 22 | 58/M | None | No | NR | NR | No | NR | LPV-RTV, HCQ | VRC | Alive | Aspergillus spp./ND | NR | ND |
| Koehler et al. in Germany | 23 | 62/F | HTN, obesity, hypercholesterolemia, COPD | No | Yes | No | Yes | Yes | Nil | VRC | Death | A. fumigatus/pos | Neg | >2.5 |
| | 24 | 70/M | Nil | No | Yes | No | Yes | Yes | Nil | ISA | Death | A. fumigatus/pos | 0.7 | >2.5 |
| | 25 | 54/M | HTN, DM, aneurysm | Yes | Yes | Yes | Yes | Yes | HCQ, darunavir and cobicistat | CSP | Alive | A. fumigatus/pos | Neg | >2.5 |
| | 26 | 73/M | HTN, COPD, hepatitis B | No | Yes | No | Yes | Yes | Nil | VRC | Death | A. fumigatus/pos | Neg | ND |
| | 27 | 54/F | No | No | Yes | No | Yes | Yes | Ribavirin, LPV-RTV | CSP | Alive | NG/neg | 2.7 | ND |

(continued on next page)
| Study/case | Age/gender | Underlying disease | Systemic steroid | Images | MV | RRT | Anti-COVID-19 | Antifungal treatment | Outcome | Culture/PCR (CT) | Galactomannan index |
|------------|------------|-------------------|-----------------|--------|----|-----|---------------|--------------------|---------|----------------|-------------------|
| Lahmer et al. in Germany | 28 | 80/M | Suspect pulmonary fibrosis | No | Yes | NR | Yes | NR | NR | Liposomal AMB | Death | A. fumigatus/ND | 1.5 | 6.3 |
| Lescure et al. in France | 29 | 70/M | No | No | Yes | NR | Yes | NR | NR | Liposomal AMB | Death | A. fumigatus/ND | <0.5 | 6.1 |
| Blaize et al. in France | 30 | 80/M | Thyroid cancer | NR | Yes | No | Yes | Remdesivir | VRC - > ISA | Death | A. flavus/NR | NR | NR |
| Antinori et al. in Italy | 31 | 74/M | Myelodysplastic syndrome, No Hashimoto’s thyroiditis, HTN | Yes | NR | Yes | NR | NR | NR | Death | A. fumigatus/pos | NR | Neg |
| Prattes et al. in Austria | 32 | 73/M | DM, HTN, hyperthyroidism, obesity | No | Yes | No | Yes | LPV-RTB, HCQ | Liposomal AMB | Death | A. fumigatus/NR | 8.6 | NR |
| Meijer et al. in Netherland | 33 | 70/M | COPD, sleep apnea, DM, No CKD, HTN, ischemia heart disease, obesity | Yes | No | Yes | NR | AZI, HCQ | VRC | Death | A. fumigatus/NR | Neg | ND |
| | 34 | 74/F | Polyarthrosis | No | Yes | No | Yes | HCQ | VRC - > CSP | Death | A. fumigatus^/NR | Neg | >3.0 |

^ Azole-resistant.

HTN, hypertension; LPV-RTV, lopinavir-ritonavir combination; AZI, azithromycin; HCQ, hydroxychloroquine; DM, diabetes mellitus; ARDS, acute respiratory distress syndrome; MV, mechanical ventilation; RRT, renal replacement therapy; VRC, voriconazole; CSP, caspofungin; CKD, chronic kidney disease; AML, acute myeloid leukemia; IPA, invasive pulmonary aspergillosis; ISA, isavuconazole; AFG; anidulafungin; AMB, amphotericin B; NSCLC, non-small cell lung cancer; RT, radiotherapy; PCR, polymerase chain reaction for Aspergillus; CT: cycle time values; BAL, bronchoalveolar lavage fluid; NG: no growth; neg: negative; pos: positive; NR, no report; ND, not done.
also the most commonly used antifungal agent, aspergillosis caused byazole-resistant *Aspergillus* is also possible.

**The challenge in the management of pulmonary aspergillosis among COVID-19 patients**

**Adverse effects**

Many drugs that have been proposed for treatment of COVID-19 are reported to cause cardiac adverse events. For example, hydroxychloroquine, azithromycin and protease inhibitors such as lopinavir/ritonavir have the potential for unwanted QT-interval prolongation and risk of drug-induced Torsade de Pointes, ventricular arrhythmias, and sudden cardiac death. The chloroquine and hydroxychloroquine can cause direct myocardial toxicity. However, in a large cohort of 201 COVID-19 patients in New York, the maximum QTc during treatment was significantly longer in the chloroquine/hydroxychloroquine and azithromycin combination group vs the chloroquine/hydroxychloroquine monotherapy group (470.4 ± 45.0 ms vs. 453.3 ± 37.0 ms, p = 0.004). Seven patients (3.5%) required discontinuation of these medications due to QTc prolongation. Patients with pre-existing heart disease are especially susceptible to drug-induced arrhythmias. This is important because up to one-third of patients with COVID-19 have cardiac injury or cardiomyopathy, which can further increase the risk of cardiac arrhythmias. Clinical protocols to manage COVID-19 and avoid cardiac adverse effects are recommended. If baseline electrocardiographic testing reveals a moderately prolonged QTc (QTc > 480 ms for female, > 470 ms for male, but < 500 ms), optimization of medications and electrolytes may permit therapy. If the QTc is markedly prolonged (QTc > 500 ms or increased by > 60 ms), the above-mentioned drugs that might further prolong QTc should be avoided.

**Drug–drug interaction**

Voriconazole is a standard first-line treatment for IPA but intravenous therapy can prolong the QT interval and the potential for drug–drug interactions. For COVID-19 patients treated with voriconazole for IPA, another concern would be increased the risk for QTc prolongation for these patients, especially in the presence of baseline QTc ≥ 450 ms. Cytochrome P450 (CYP) 3A4 is the most prevalent metabolizing enzyme in the human liver. CYP3A4-mediated drug interactions would be of considerable clinical importance in COVID-19 patients using lopinavir/ritonavir, azithromycin, and voriconazole that are highly dependent on CYP3A4 for clearance and also are potent inhibitors of CYP3A4 metabolism. However, in a randomized study for 30 healthy male volunteers in the UK, coadministration of azithromycin does not affect the steady-state pharmacokinetics of voriconazole. Therefore, further study should investigate the safety of using voriconazole in COVID-19 patients receiving anti-SARS-CoV-2 agents. Additionally, isavuconazole—a new antifungal mold azole, which does not have the side effect of QTc prolongation, may deserve further investigation regarding its potential role in the treatment of COVID-19 complicated IPA.

**Conclusions**

During this COVID-19 pandemic, aspergillosis can cause co-infection with SARS-CoV-2 despite these patients who did not have a traditional risk factor of aspergillosis infection. Respiratory specimens for mycologic studies, such as culture, galactomannan tests, and PCR can help early diagnosis. The outcome of COVID-19-associated pulmonary aspergillosis is poor and the recommend antifungal agent—voriconazole should be used carefully in the concern of complicated drug–drug interaction and enhancing cardiovascular toxicity on to anti-SARS-CoV-2 agents.

**References**

1. WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Accessed 2 August 2020].
2. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924.
3. Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents 2020;55:105946.
4. Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect 2020;53:505–12.
5. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Co-infection and other clinical characteristics of COVID-19 in children. Pediatrics 2020;146:e20200961.
6. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020;81:266–75.
7. Ozaras R, Cirpin R, Duran A, Duman H, Arslan O, Bakcan Y, et al. Influenza and COVID-19 co-infection: report of six cases and review of the literature. J Med Virol 2020 Jun 4. https://doi.org/10.1002/jmv.256125.
8. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020 May 2;ciaa530. https://doi.org/10.1093/cid/ciaa530.
9. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among COVID-19 cases. Virus Res 2020;285:198005.
10. Chaudhary WA, Chong PL, Mani BI, Asli R, Momin RN, Abdullah MS, et al. Primary respiratory bacterial coinfections in patients with COVID-19. Am J Trop Med Hyg 2020 Jun 3. https://doi.org/10.4269/ajtmh.20-0498.
11. Chen FL, Wang CH, Hung CS, Su YS, Lee WS. Co-infection with an atypical pathogen of COVID-19 in a young. J Microbiol Immunol Infect 2020 May 21;S1684–11182(20):30121–3. https://doi.org/10.1016/j.jmii.2020.05.007.
12. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
49. Brown JD, Lim LL, Koning S. Voriconazole associated torsades de pointes in two adult patients with haematological malignancies. *Med Mycol Case Rep* 2014;4:23–5.

50. Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. *Clin Infect Dis* 2004;39:e49–52.

51. Gueta I, Loebstein R, Markovits N, Kamari Y, Halkin H, Livni G, et al. Voriconazole-induced QT prolongation among hematologic patients: clinical characteristics and risk factors. *Eur J Clin Pharmacol* 2017;73:1181–5.

52. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. *Drugs* 2003;63:769–802.

53. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. *Clin Pharmacokinet* 2007;46:681–96.

54. Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. *Br J Clin Pharmacol* 2003;56(Suppl 1):30–6.